About Lindis Blood Care
Lindis Blood Care is developing a medical device to be used in oncology for the operation of tumours in order to open up the possibility of self-blood administration of blood collected during the operation. The product consists of a combination of an antibody and filter and serves to remove cancer cells from the blood.
Press releases
Press
Lindis Blood Care Announces Successful Financing for its Tumor-Cell-Removal Medical Device, CATUVAB®
First closing of funding round supported by Brandenburg Kapital, High-Tech Gründerfonds, existing and new private investors; second closing expected by the end of Q1 2025
Funds to be used in preparing for upcoming approval and product launch of CATUVAB® in Europe
CATUVAB® is a novel approach designed to be a safe and cost-effective way to reliably remove tumor cells from autologous blood
Hennigsdorf, Germany – 12 December, 2024: Lindis Blood Care, a company aiming
Press
Lindis Blood Care successfully closes follow-on financing round
Funding round supported by High-Tech Gründerfonds (HTGF), Brandenburg Kapital and several private investors, showing their continued commitmentFunds to be mainly used to complete ongoing REMOVE study with CATUVAB®, extend clinical program, complete CE marking procedure, start FDA market application process and support partnering activitiesCATUVAB® is a novel approach designed to be a safe and cost-effective way to reliably remove tumor cells from autologous blood
Hennigsdorf, Germa
Press
Over 5 Million Euros For Lindis Blood Care: Development Of A New Product For The Removal Of Tumor Cells From Surgical Blood
Clinical development of the product CATUVAB secured
CATUVAB is designed to enable tumor cell free return of autologous blood collected during a surgery without significantly altering standard surgical procedures
High-Tech Gründerfonds (HTGF), Brandenburg Kapital and five private investors participated in a capital increase
Including the ILB grants from the "ProFIT" program of the European Regional Development Fund (3.3 million euros), the Company receives a total of more than 5 million
Info & Contact
Address
Neuendorfstraße 20B
16761 Hennigsdorf
Deutschland
16761 Hennigsdorf
Deutschland
In portfolio
23. Sep 2019
Sector
Dr. Angelika Vlachou
Partner